Active, not recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779· Phase 3· Incyte Corporation· Source
Active, not recruiting
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
NCT07288203· Phase 2· Iovance Biotherapeutics, Inc.· Source
Completed
A Phase 1 Study of ATV-1601, in Patients with Advanced Cancer that have AKT1 E17K Mutations
2025-521480-12-00· Phase 1· Atavistik Bio Inc.· Source
Completed
A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors
NCT04892017· Phase 1/2· Deciphera Pharmaceuticals Inc.· Source
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154· Phase 2· Astellas Pharma Global Development, Inc.· Source
Completed
A trial to learn how safe AZD0022 is, how well it works, and how it moves throughout the body over time in adults with tumors that have a KRAS-G12D mutation, when given alone and with other cancer drugs
NCT06599502· Phase 1/2· AstraZeneca AB· Source
Active, not recruiting
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
NCT06726265· Phase 3· Immutep S.A.S.· Source
Completed
N/A
2024-513121-22-00· Phase 2· Gilead Sciences Inc.· Source
Completed
Prospective phase IIb study to evaluate the efficacy of laparoscopic electrochemotherapy in the treatment of locally advanced pancreatic cancer - ECT-LAPC Laparoscopic
2024-519067-17-00· Phase 2· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source
Completed
An Open-Label, Multicenter, Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1604 in Adults with Advanced Melanoma
2024-511949-19-00· Phase 1· Sairopa B.V.· Source
Completed
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
NCT06433219· Phase 2· EMD Serono Research & Development Institute, Inc.· Source
Active, not recruiting
A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients
NCT06540391· Phase 1· Microbiotica Ltd· Source
Active, not recruiting
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
NCT06483334· Phase 1/2· Merck Sharp & Dohme LLC· Source
Completed
Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with
osteosarcoma. ( CabOSTar )
NCT06341712· Phase 2· Ipsen Innovation· Source
Completed
A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1
NCT05870748· Phase 2· Sutro Biopharma Inc.· Source
Completed
A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)-approved Keytruda®in participants with stage Ⅱ and Ⅲ skin cancer requiring adjuvant treatment (therapy applied after initial treatment of cancer to suppress the regrowth of tumor) with pembrolizumab.
2023-506881-30-00· Phase 1· H e x a l AG· Source
Completed
A Phase 2 Trial of BDC-1001 as Single Agent and in Combination with Pertuzumab in Subjects with Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Previously Treated with Trastuzumab Deruxtecan
NCT05954143· Phase 2· Bolt Biotherapeutics Inc.· Source
Active, not recruiting
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
NCT06004661· Phase 2· Novartis Pharmaceuticals· Source
Completed
FIH study of ALE.C04 anti-CLDN1 mAb monotherapy or in combination with pembrolizumab in patients with R/M HNSCC
2023-505145-93-00· Phase 1/2· Alentis Therapeutics AG· Source
Completed
A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
2023-506092-10-00· Phase 2· Ascendis Pharma Oncology Division A/S· Source
Completed
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer
2022-502453-33-00· Phase 2· Genmab A/S· Source
Completed
TACTIVE-U: An Umbrella Study to Investigate the Safety and Antitumor Activity of ARV-471 in Combination With Other Medicines in Adults With ER+ Advanced or Metastatic Breast Cancer, Sub-study B (ARV-471 and Ribociclib)
NCT05573555· Phase 1/2· Pfizer Inc.· Source
Completed
A Study to Evaluate Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or Refractory Multiple Myeloma
2023-503689-21-00· Phase 1/2· F. Hoffmann-La Roche AG· Source
Completed
A Phase 1b/2 Study of BMS-986442 with Nivolumab with or without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
2022-503108-26-00· Phase 1/2· Bristol-Myers Squibb Services Unlimited Company· Source
Completed
Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer
NCT06059547· Phase 2· CatalYm GmbH· Source
Recruiting
Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma
NCT06341764· Phase 2· National Cancer Institute, Naples· Source
Completed
Clinical trial of MK-7648A in adults and children with skin cancer
NCT05665595· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
2022-502267-37-00· Phase 1/2· K-Group Beta Inc.· Source
Completed
A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer
NCT05634499· Phase 2· Hoffmann-La Roche· Source
Active, not recruiting
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
NCT05845814· Phase 1/2· Merck Sharp & Dohme LLC· Source
Completed
A Phase 1 Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in combination with the KRAS-G12C Inhibitor Sotorasib in Patients with Advanced Solid Tumors and a KRAS-G12C Mutation
NCT05480865· Phase 1· Navire Pharma Inc.· Source
Completed
Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies
NCT05577182· Phase 1· Incyte Corporation· Source
Completed
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION)
2023-508528-36-00· Phase 3· Merck Healthcare KGaA· Source
Completed
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
NCT05668585· Phase 1· C4 Therapeutics, Inc.· Source
Completed
Clinical study to investigate the efficacy of botensilimab (AGEN1181) in patients with advanced melanoma refractory to prior checkpoint inhibitor therapy
2022-500652-37-00· Phase 2· Agenus Inc.· Source
Completed
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRα) Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)
NCT05200364· Phase 1· Sutro Biopharma Inc.· Source
Terminated
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
NCT05171075· Phase 3· Anthos Therapeutics, Inc.· Source
Completed
A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma
NCT05309421· Phase 2· Evaxion Biotech A/S· Source
Active, not recruiting
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
NCT05450692· Phase 3· AstraZeneca· Source
Completed
Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102)
NCT05111626· Phase 3· Amgen Inc.· Source
Completed
A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorectal Cancer
NCT05328908· Phase 3· Bristol Myers Squibb International Corporation· Source
Active, not recruiting
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
NCT05142696· Phase 1/2· Novartis Pharmaceuticals· Source
Completed
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
NCT04919512· Phase 2· Janssen Research & Development, LLC· Source
Completed
Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma.
2024-516166-11-00· Phase 3· Advenchen Laboratories LLC· Source
Completed
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
NCT05375903· Phase 1· UroGen Pharma Ltd.· Source
Active, not recruiting
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
NCT05155254· Phase 3· IO Biotech· Source
Terminated
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
NCT05171049· Phase 3· Anthos Therapeutics, Inc.· Source
Recruiting
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
NCT04879329· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source
Completed
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
NCT05298423· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
NCT05198934· Phase 3· Amgen· Source
Showing 50 of 102.